However, significant discoveries in the last century have dramatically changed the outlook for PC patients, including the hormone-dependent nature of PC [3] and the high therapeutic efficacy in targeting this key feature, specifically the high expression and frequent genetic amplification of the androgen receptor (AR). The gene discussed is AR; the disease is pachyonychia congenita.